Information Provided By: 
Fly News Breaks for July 22, 2019
ADPT
Jul 22, 2019 | 06:43 EDT
BofA/Merrill analyst Derik de Bruin initiated Adaptive Biotechnologies with a Buy rating and a price target of $45. The analyst cites the company's immune-medicine platform working to help recognize and react to virtually any cancer or pathogen threat, saying the ability to potentially detect and treat almost any disease involving the immune system positions it as an "intriguing healthcare growth story."
News For ADPT From the Last 2 Days
There are no results for your query ADPT
